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Abstract 
Background and Aims. Cirrhotic patients with acute decompensation frequently 
develop acute-on chronic liver failure (ACLF), which is associated with high mortality 
rates. Recently, a specific score for these patients has been developed using the 
CANONIC study database. The aims of this study were to develop and validate the 
CLIF-C AD score, a specific prognostic score for hospitalised cirrhotic patients with 
acute decompensation (AD) but without ACLF and, to compare this with the Pugh, 
MELD and MELD-Na scores. 
Methods. The derivation set included 1,016 CANONIC study patients without ACLF. 
Proportional hazards models considering liver transplantation as a competing risk was 
used to identify score parameters. Estimated coefficients were used as relative weights 
to compute the CLIF-C ADs. External validation was performed in 225 cirrhotic AD 
patients. CLIF-C ADs was also tested for sequential use. 
Results. Age, serum sodium, white-cell count, creatinine and INR were selected as the 
best predictors of mortality. The C-index for prediction of mortality was better for CLIF-
C ADs compared with Pugh, MELD and MELD-Nas at predicting 3- and 12-month 
mortality in the derivation, internal validation and the external dataset. CLIF-C ADs 
improved in its ability to predict 3-month mortality using data from days 2, 3-7 and 8-15 
(C-index: 0.72; 0.75 and 0.77 respectively).  
Conclusions. The new CLIF-C ADs is more accurate than other liver scores in 
predicting prognosis in hospitalised cirrhotic patients without ACLF. CLIF-C ADs 
therefore may be used to identify a high-risk cohort for intensive management and a 
low-risk group that may be discharged early. Patients with cirrhosis who require 
admission to the hospital with acute decompensation (ascites, gastro-intestinal 
bleeding, hepatic encephalopathy and/or acute bacterial infections) have widely 
variable prognosis dependent on whether they have acute-on chronic liver failure 
(ACLF) [1-3], which is diagnosed using the CLIF Consortium organ failure score (CLIF-
C OFs) [4-5]. In the CANONIC study, which was performed in patients with acute 
decompensation of cirrhosis with and without ACLF, the 3-month mortality of patients 
with ACLF was 51% [5]. A specific score to predict prognosis in patients with ACLF, the 
CLIF-C ACLF score (CLIF-C ACLFs) has been developed [3]. 
 
In the CANONIC patients with acute decompensation who did not develop ACLF, the 
28-day mortality was 4.6% but this increased to 12.6% at 3-months, 18.3% at 6 months 
and 27.6% at 1-year (AD patients) [5]. These data suggest that some patients with AD 
are also at high risk of short-term mortality that should to be recognised early and 
treated as potentially high-risk patients requiring closer monitoring and interventions to 
prevent progression to ACLF and death. On the other hand, the patients with AD who 
are at low risk of mortality may be discharged early, potentially saving resources and 
distress for the patients and their relatives. At present a specific prognostic score 
focussing the AD patients is an unmet need [2,6]. 
 
The main objective of this study was therefore, to develop a new score (CLIF-
Consortium score for AD patients, CLIF-C ADs) with a higher prognostic accuracy than 
the currently used scoring systems such as the MELDs [7], MELD-Nas [8] and Child-
Pugh score (CPs) [9]. The study therefore had three main aims. First, to develop a 
scoring system for sequential use based upon clinical and biochemical data to 
prognosticate on the survival of patients with AD who did not fulfil criteria for the 
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diagnosis of ACLF (CLIF-C ADs) [5]. Second, to compare the prognostic accuracy of 
CLIF-C ADs with MELDs, MELD-Nas and CPs. Third, to validate the prognostic 
accuracy of the CLIF-C ACLFs in two prospective external cohorts of hospitalized 
cirrhotic patients with AD and no ACLF. We used the CANONIC study database to 
develop this score because it had over 1000 prospectively included patients with AD 
that were followed for 1-year from multiple centres in Europe. The validation sets were 
drawn from hospitals in Barcelona (Hospital Clinic) and London (Royal Free Hospital). 
 
METHODS 
Study populations. 
The study was performed in cirrhotic patients with acute decompensation from two 
different populations. The CANONIC study population included 1,349 cirrhotic patients 
from 29 European hospitals who had developed acute decompensation leading to 
hospitalization and were prospectively followed-up to 1-year. Reasons for exclusion 
were: patients with decompensated cirrhosis admitted for a scheduled procedure or 
treatment, patients with hepatocellular carcinoma outside Milan criteria, severe chronic 
extra-hepatic disease, HIV infection or immunosuppressive therapy, and patients who 
refused to participate [5]. 
Ethical review boards in individual countries approved the study [5]. The CANONIC 
patients who did not develop an ACLF episode at enrolment and had all the data 
required to compute the studied scores at study enrolment were included in the score 
derivation set [5]. The population used for external validation consisted of 225 patients 
admitted to two European hospitals with an acute decompensation of cirrhosis and not 
presenting an ACLF episode.  
 
Statistical methods 
All the variables used in statistical analyses were obtained at the time of study 
enrolment, which coincides with hospital admission in most patients (98%). 
 
In the CANONIC series, a simplification of the CLIF-SOFA score [10] named CLIF-C 
OF score, was used to diagnose ACLF and classify the patients based on their 
severity. CLIF-C OF score included 6 sub-scores – one for each organ/system (liver, 
kidney, brain, coagulation, circulation and respiration) – each of them ranging from 1 to 
3 with an aggregate score ranging 6-18. The categories included in CLIF-C OF score 
sub-scores and the corresponding cut-off values were derived from a consensus and 
the aggregate score proved to accurately predict mortality and ACLF onset in patients 
with AD [3,5]. 
 
With the purpose of deriving a simple, specific prognostic score for cirrhotic patients 
with AD and without ACLF including only objective clinically relevant predictors, we 
assessed the association between each of the patients’ clinical characteristics and 
laboratory parameters at study enrolment and the mortality observed at each main 
time-point (28, 90, 180 and 365 days). The objective was to select a limited group of 
predictors related to both short and long-term mortality with a reduced co-linearity. 
Score parameters were then to be chosen among these predictors. To assess if the 
predictive ability of CLIF-C AD score could be improved by clinical subjective 
parameters, such as ascites or encephalopathy, all factors significantly associated with 
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mortality in the univariate analysis and not selected for the final score model were 
individually added to the model, testing the change in the corresponding C-index. 
In all univariate statistical comparisons, Chi-square test was used for categorical 
variables, Student’s t-test and Mann-Whitney test for continuous variables. McNemar 
test and paired t-test were used to compare repeated measurements of categorical and 
continuous variables, respectively. Among the CANONIC patients with AD and without 
ACLF, 160 Patients (15.7%) underwent a liver transplantation within 1 year after their 
hospitalization, 76 in the first 3 months (7.5%), 40 between 3 and 6 months (3.9%) and 
44 (4.3%) after 6 months. As the study was performed in many centres around Europe, 
there was no agreed prioritization for transplantation. The decision to transplant a 
particular patient or not, and whether they were prioritized was decided by individual 
centres. So, in order to identify the main predictors for mortality and to estimate the 
corresponding effects adjusting for the impact of liver transplantation as well as for the 
geographic differences in transplant dynamics, a proportional-hazards model 
considering liver transplantation as a factor “competing” with mortality risk was used to 
select score parameteres [11,12]. The group of baseline factors significantly (p<0.05) 
associated with mortality at main study time-points and with a limited internal co-
linearity (pairwise Pearson’s correlation coefficients of 0.5 or lower) was used to fit the 
final model. PH-CR models including all the selected factors were fitted applying a 
forward step-wise selection method with p-in=0.05 and p-out=0.1. The coefficients 
estimated for each factor in the 90-day model, which provided the best predictive 
ability, were used as relative weights to compute the CLIF-C AD score.  
 
The calibration of CLIF-C AD score was assessed by comparing the actual observed 
risk and the average probability of dying at different time-points predicted by the score. 
The observed and predicted probabilities were also compared across different levels of 
CLIF-C AD score by means of the Hosmer-Lemeshow χ2 test to assess the 
corresponding goodness-of-fit.  
  
Harrell’s concordance index (C-index) was used to assess the score discrimination 
ability [13, 14]. Since a PH-CR model was used, C-index values and the corresponding 
95% Confidence Intervals (CI’s) were estimated treating the transplanted patients as 
censored at the end of the follow-up, assuming that none of them could die before [11]. 
Statistical comparisons of C-index between CLIF-C AD, CLIF-OF, MELD, MELD-
Sodium and Child-Pugh scores were carried out for the main study time-points using 
the Integrated Discriminating Improvement (IDI) statistic [14]. A confirmatory analysis 
was carried out to assess the discrimination ability of CLIF-C ADs and of the other 
scores by estimating and comparing the corresponding Areas Under the ROC curves 
(AUROCs) for the 90-day mortality end-point which was used to fit the final score 
model [15].  
 
Internal and External Validation of the CLIF-AD score 
Both an internal and an external validation of CLIF-C AD score were carried out [15]. A 
sample of 500 patients randomly selected from the CANONIC non-ACLF population 
was used to internally validate the CLIF-C AD score comparing the C-index estimates 
with those obtained for MELDs, MELD-NAs and CPs by means of the same methods 
applied to the CANONIC data. The external validation was carried out applying the 
same statistical techniques as for the internal validation to an external sample of 225 
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patients hospitalized for an acute decompensation of cirrhosis without ACLF and 
showing similar clinical characteristics as the CANONIC patients. The patients included 
in this external validation set came from prospectively collected data from two different 
European centers, the Royal Free Hospital, London (97 patients) and the Hospital 
Clinic, Barcelona (128 patients). 
 
Validation of the CLIF-AD score for sequential use 
The prognostic ability of CLIF-C AD and MELD scores for sequential use was 
assessed using the sub-set of CANONIC patients without ACLF at enrolment and data 
available at the time of enrolment, at 48-hours, 3-7 days and at 8-15 days after 
enrolment. Post-enrolment C-indexes for 1-year mortality were compared with baseline 
(enrolment) by means of paired t tests. 
 
RESULTS 
Study populations 
The derivation set included 1,016 of the 1,349 CANONIC study patients who did not 
present ACLF at study enrolment and had all the data required to compute the studied 
scores [3,5]. The etiology of cirrhosis was mainly alcoholic or chronic hepatitis C (75%, 
Table 1). In the remaining patients, the causes of cirrhosis were chronic hepatitis B (67 
patients, 6.6%), cryptogenic (61, 6.0%), NASH (55, 5.4%), primary billiary cirrhosis (24, 
2.4%) and other causes (). Among the 67 patients with HBV, 29  (43.3%) were 
receiving treatment with anti viral drugs within 3 months prior to enrollment: 13 (19.4%) 
received Entecavir, 10 (14.9%) Tenofovir, 4 (6.0%) Lamivudine (3 alone and one in 
combination with Tenofovir) and 2 (3.0%) Telbivudine (one alone and one in 
combination with Entecavir). The database used for external validation included 225 
non-ACLF patients from two-centres. Etiology of cirrhosis in these patients was similar 
to that in the derivation set. All patients from both the derivation and the external 
validation cohorts were followed-up for one-year. Criteria for the inclusion/exclusion in 
the validation set were those applied to the CANONIC study. Patients in the external 
validation cohort were more frequently male, had a higher rate of hepatic 
encephalopathy grade III-IV, higher levels of white blood cells and INR than the 
CANONIC cohort. The use of vasopressors was significantly higher in the derivation 
set. However, the rest of clinical and lab parameters at admission as well as MELDs, 
MELD-Nas and CPs and mortality rates were similar in the derivation and validation 
sets, except for 1-year mortality rate, which was higher in the CANONIC cohort (Table 
1). 
Development of the CLIF-C ADs 
The new CLIF-C AD score was developed with the purpose of identifying a limited 
number of independent predictors. Therefore, univariate analyses compared survivors 
and non-survivors at the main study end-points (mortality rates at 90, 180 and 365 
days) including all the parameters used to compute the CLIF-C OFs as well as all 
clinical characteristics and lab parameters at patients’ enrolment. The 28-day mortality 
was very low (4%, 47 patients). Therefore, this was not taken into account as the main 
outcome for multivariate modelling. The baseline factors significantly associated with 
short- and long-term mortality were age, ascites (clinically diagnosed), GI-bleeding, 
serum sodium, creatinine, INR, serum potassium, white-cell count and C-reactive 
protein (Supplementary Table 1).  After fitting an initial CR-PH model with all these 
factors, age, serum sodium and log-transformed white-cell count, creatinine and INR 
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were selected as the best predictors. Surprisingly, bilirubin was not included in the sub-
set of the best predictors: this was probably due to the smaller effect-size observed at 
the different time-points (Figure 1). 
 
The CLIF-C ADs was computed by applying model coefficients. Although in our series 
the extreme values were from 23.4 to 81.6, the potential values in some patients might 
exceed these limits and be negative or higher than 100. The score was then trimmed 
between 0 and 100, since lower and upper values did not modify the expected 
probabilities of dying by more than 1%. In the whole series the mean CLIF-C ADs was 
51.2 (SD: 8.7). Supplementary Figure 1 shows the CLIF-C ADs histogram in our series.  
 
The equation for CLIF-C ADs is: 
 
CLIF-C ADs = 10*[0.03*Age{years} + 0.66*Ln(Creatinine{mg/dL}) + 1.71*Ln(INR) + 
0.88*Ln(WBC{109cells/L}) -0.05*Sodium{mmol/L} + 8] 
 
The probability of death at time “t” was estimated by the equation: 
P= 1-e(-CI(t) * exp(β(t)*CLIF-C ADs)) 
 
CI(t) and β(t) are the cumulated baseline hazard and the score coefficient estimated by 
the model fitted for time t. At the main time-points they are: CI(90)=0.00056, 
β(90)=0.1007; CI(180)=0.00173, β(180)=0.0889; CI(365)=0.00879, β(365)=0.0698. 
 
An online application to estimate the predicted death rate at time ‘t’ based on CLIF-C 
ADs is available at the CLIF-Consortium website: http://www.clifconsortium.com/ 
 
Calibration of the CLIF-C ADs 
The predicted and observed probabilities of death at 1-year were similar across the 
different levels of CLIF-C ADs (Supplementary Figure 2): Hosmer-Lemeshow χ2=13.1, 
p=0.12). The probabilities of death estimated for the mean value of CLIF-C ADs were 
almost identical to the overall mortality rates observed at all the main study time-points: 
90-day (0.12 vs 0.13), 6-month (0.19 vs 0.18) and 1-year (0.31 vs 0.28).  
 
Discrimination ability of CLIF-C ADs. Comparison with CLIF-OFs, MELDs, MELD-
Nas AND CPs.  
The C-Index of CLIF-C ADs for 28-day, 90-day, 6-month and 1-year mortality (0.75, 
0.73, 0.71 and 0.67) was significantly better than those corresponding to CLIF-C OFs 
(0.68 [p<0.001], 0.61 [p<0.001], 0.58 [p<0.001] and 0.56 [p<0.001]). CLIF-C ADs 
significantly improved the predictive discrimination of all the other scores at 90 days 
and on longer term (Table 2). In particular, the improvements of 6 to 10 points in C-
index values with respect to MELDs were consistently significant at all time-points. 
Figure 2 shows the corresponding percent improvement obtained with CLIF-C ADs in 
prediction error rate with respect to the other scores (computed as percent reduction in 
discordance rate of CLIF-C ADs vs Reference score, i.e. 100 x [C-indexCLIF-C ADs – C-
indexREF] / [1 - C-indexREF]). CLIF-C ADs consistently improved the prediction error 
rates observed for MELDs and CPs (the relative improvements ranged between 8% 
and 14.5% at the different time-points). The percent reduction in discordance rates of 
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CLIF-C ADs as compared to those observed with MELD-Nas were lower (between 4% 
and 9%) but still consistent across all time-points.  
 
The analysis carried out by comparing the AUROCs corresponding to CLIF-C AD 
score, MELD, MELD-Na and CP score for 90-day confirmed the superiority of CLIF-C 
ADs and the improvement in predictive ability with respect to the other scores (Figure 
3).  
 
We explored different cut-off values of CLIF-C ADs potentially useful to discriminate the 
sub-groups of patients at a lowest and highest risk of dying. In the 274 patients (27.0%) 
with a CLIF-C ADs equal to or lower than 45, 90-day mortality rate (1.8%, 95%CI: 0.8% 
- 4.2%) was 5 times lower than in whole series of AD patients. The corresponding 
survival at 6 (94.2%; 95%CI: 90.7% - 97.4%) and 12 months (85.4%; 95%CI: 80.7% - 
89.1%) were also very high. On the other hand, a group of 163 patients (16%) with a 
score of or 60 or higher presented a 3-fold increase as compared to the overall 
mortality rates. Their mortality at 3, 6 and 12 months was 31.3% (95%CI: 24.7%- 
38.8%), 42.9% (95%CI: 35.6%-50.6%) and 50.9% (95%CI: 43.3%-58.5%), 
respectively. The addition of other predictors not included in the final model did not 
significantly improve the performance of the CLIF-C AD score (Supplementary Table 
2). 
 
Validation of the CLIF-ACLFs  
The comparative C-index estimates for the internal and external validation cohorts are 
shown in Table 3. In the 500 CANONIC patients without ACLF randomly selected for 
the internal validation analysis, the predictive ability of CLIF-ACLF score at each main 
time point was significantly better than those corresponding to MELD, MELD-Na and 
CP score. The C-index estimates for all the scores at all time-points were similar to 
those obtained from the whole population of CANONIC patients. 
 
The external validation analysis included 225 patients without ACLF. CLIF-C AD score 
improved the predictive ability of the other 3 scores, although this improvement was 
statistically significant only for 90-day mortality. This is probably due to the fact that the 
estimates have been obtained with a limited sample size. Moreover, all C-index 
estimates, in particular those obtained for the CLIF-C AD score, were coherent and 
similar to those obtained for the whole CANONIC population and for the internal 
validation sample.  
 
Sequential use of the CLIF-ACLFs 
Table 4 reports the C-index estimates for the CLIF-ADs and MELDs computed at 
enrolment and at 48 hours, 3-7 days and 8-15 days after enrolment in the 344 
CANONIC study patients with AD at enrolment and post-enrolment follow-up clinical 
and laboratory data. When used sequentially, CLIF-C ADs improved its predictive 
performance, with statistically significant results at 1-year. These findings were not 
observed with regards to MELD. 
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DISCUSSION 
The present study used the data acquired in the CANONIC study [3,5] to focus on a 
group of patients with acutely decompensated cirrhosis with no ACLF and has 
generated a validated new score, the CLIF-AD score, which can be used to 
prognosticate on the medium (3-6 months) and long term (1 year) survival of these 
patients. The score also shows that it retains its accuracy when it is updated 
sequentially suggesting that the score responds to potential clinical interventions that 
may affect outcome. The CLIF-C AD score was validated both externally and with an 
internal resampling from the CANONIC dataset, since imbalances found between the 
derivation and the external validation sets might have affected the external validation 
results. With further validation, this score may be useful in conjunction with the CLIF-C 
Organ failure score (CLIF-C OFs) and the CLIF-C ACLF score (CLIF-C ACLF) to define 
the prognosis of a cirrhotic patient who is hospitalised with acute decompensation of 
cirrhosis [3]. An algorithm how this score may be used in combination with the CLIF-C 
ACLF score is illustrated in Figure 4. In order to use this score effectively, the scores 
should be updated on a daily basis. An online calculator and an app are under 
development. Thus, the CLIF-C OF score should be applied to all cirrhotic patients that 
are admitted to the hospital with an acute decompensation. This will allow the 
separation of patients into a group that has ACLF and a group that does not; referred to 
as the AD group. In those with ACLF, the 3-month mortality is about 51% and the CLIF-
C ACLF score has been validated to provide prognostic information in these patients 
[3,5]. In those without ACLF, the 3-month mortality is about 13% and we propose that 
the CLIF-C ADs should be applied to these patients to provide prognostic information 
[5]. The score allowed the identification of a large group of patients (274, 27%) with a 
very low 3-month mortality (CLIF-C ADs <45, survival rate 98.2%) suggesting that 
these patients could be discharged home early providing significant healthcare savings, 
reducing risk of nosocomial infections and distress to the patient and the family [6]. On 
the other hand, a high-risk group was also identified (163 patients, 16%; CLIF-C 
ADs>=60; 3-month survival rate: 68.7%), showing a 90-day mortality rate similar to that 
reported by Moreau et al. [5] in patients with ACLF grade 1. These patients represent a 
unique population to assess new early interventions to prevent progression to multi-
organ failure and death or selected for work up early for liver transplantation. This 
hypothesis will need to be tested in large prospective studies. 
 
The general principles behind developing the CLIF-C ADs were to ensure that it would 
be simple to use and provide prognostic information using variables that can be easily 
available to the clinicians who first see the patients at the time of admission to the 
hospital. The score should be able to provide figures estimating risk of mortality and 
also allow an easy stratification of patients into high and low risk groups. Most 
importantly, the new score should provide prognostic information that improves upon 
the best scoring systems available, the MELD, MELD-Na and the CP score [3].  
 
As already observed for ACLF patients [17], the factors independently associated with 
poor prognosis in AD patients can be also considered under the PIRO concept. ‘P’ in 
PIRO refers to Predisposition. It was important to note that only age had an important 
weight in predicting mortality as was also observed in the CLIF-C ACLF score. The 
aetiology of the underlying liver disease did not have discriminatory ability. It is notable 
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that the present series is representative of typical patients in the West with relative 
paucity of patients with Hepatitis B virus infection. Validation in this cohort will be 
required in future studies. ‘I’ refers to Injury. The presence or the absence of a 
precipitating event or the type was not associated with risk of mortality. ‘R’ refers to 
Response. As in the CLIF-C ACLF score [3], the white cell count was independently 
associated with poor outcome indicating that the higher risk patients have a more 
marked systemic inflammatory response providing perhaps insights into potential future 
targets of therapy. The white-cell count remained a significant poor prognostic marker 
independently of the presence of alcoholic liver disease or infection (data not shown). 
‘O’ refers to Organs. Consistently with previous studies, it was not surprising that 
serum sodium, serum creatinine and INR, the last two variables representing 
organ/system function, showed predictive ability. These variables are already 
components of the MELD-Na score, which have been studied extensively providing 
another validation of the approach used in the present study [7-9]. Therefore, our data 
suggest that both age and inflammatory response, the latter measured using the white-
cell count, add discrimination ability to organ function predictors, explaining the higher 
accuracy of CLIF-C ADs with respect to other liver scores. Through the final model 
including these 5 variables, a new score (CLIF-C ADs) ranging between 0 and 100 
points, which accurately predicted the risk of mortality could be developed. In order to 
take into account the potential to change the outlook of patients with interventions such 
as treatment of the underlying disease, precipitating factors, modifying inflammatory 
response or improving organ function, we assessed the score for sequential 
measurements by showing that the mid- and long-term predictive accuracy of the CLIF-
ADs is retained or improves when measured again at 48-hours, 3-7 days and 8-15 
days. 
 
The next step was to compare the performance of this score against the current gold 
standards, the MELD, MELD-Na and the CP scores. Comparison between the CLIF-C 
AD and MELD, MELD-Na and CP score was assessed in three different ways and 
suggests the superiority of the CLIF-C ADs over the other scoring systems. First, the 
AUROC analysis clearly shows that the CLIF-C AD score was significantly more 
accurate in predicting 3-month mortality compared with MELD, MELD-Na and CP score. 
Second, the observed vs predicted mortality rates indicated by the concordance index 
in the derivation cohort showed that CLIF-C AD score was significantly more accurate 
in predicting 3-month, 6-month and 12-month mortality than MELD, MELD-Na and CP 
score. The accuracy of these observations was confirmed in the internal validation 
cohort. Concordance indices confirmed better performance of the CLIF-C AD score in 
the external validation data, which was statistically significant at predicting 3-month 
mortality against MELD and CP score. It is possible that the relatively small sample 
size and the relatively low event rate of the validation cohort account for the lack of 
statistical significance at other time point. Third, the CLIF-C AD score improved the 
performance of these other scores by 8-15% being most relevant at predicting 3-month 
mortality in both the derivation and also the validation cohorts.  
 
The assessment of the percent effect-size estimates of each variable explains the 
better performance of the CLIF-C AD score compared with the MELD and MELD-Na 
results. The effect size of age, which is not included in MELD or MELD-Na scores, was 
similar to that of creatinine and bilirubin, which are important components of both 
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scores. Additionally, creatinine and especially bilirubin showed a limited effect-size for 
mortality, probably due to the absence of high-risk patients (with ACLF) in this analysis 
population. Finally, white cell count and serum sodium, CLIF-C ADs components which 
showed the highest effect-size for mortality, are absent in CP and MELD while white-
cell count is not included in MELD-Na score.  
 
In our study, the C-index values observed for MELD and MELD-Na scores (ranging 
from 0.58 to 0.71) are among the lowest reported by other investigators [18-24]. This is 
probably related to the difference between our study and the other investigations in 
patients’ characteristics and times of score assessment. In most investigations, the 
MELD and/or MELD-Na were assessed in patients with any type of liver disease at the 
time of enrolment on the waiting list for liver transplantation. In contrast, in our study all 
patients had cirrhosis and scores were obtained in nearly all cases at the time of 
admission to the hospital for an acute decompensation of cirrhosis. Patients with an 
acute decompensation of cirrhosis are extremely unstable and they may improve or 
worsen within a few days after admission. Therefore, it is not surprising that, in our 
study, MELD and MELD-Na scores showed lower discrimination abilities as compared 
to other studies, in which scores were assessed in patients with more stable conditions. 
For instance, among the 1,016 patients included in the current analysis, 115 (11.3%) 
developed an ACLF within 28 days following study enrolment (data not shown). 
Approximately 50% of these patients died within 3 months after enrolment. On the 
other hand, in many other patients, renal and hepatic functions improved rapidly 
following standard medical treatment. 
 
 Despite the improvement of the prognostic accuracy observed with the CLIF-C AD 
score over the MELDs, MELD-Nas and CPs, in our results a significant proportion of 
incorrect predictions (26% for 90-day mortality) is still present, thus indicating the need 
for further studies on additional and/or more accurate prognostic markers in these 
patients. 
 
In summary, the data presented in this paper focussed on developing a validated, new 
scoring system using simple clinical variables that can be updated sequentially to 
determine the mortality of patients who presented with acute decompensation of 
cirrhosis and did not have ACLF. This score performs significantly better than the 
existing scoring systems. When combined with the CLIF-C OF and the CLIF-C ACLF 
score, the outlook of all patients with cirrhosis that require hospital admission with 
acute decompensation can be mapped according to the proposed algorithm and 
divided in low and high-risk cohorts. The proposed algorithm should be validated 
prospectively in large studies. 
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Figure Legends 
 
Figure 1. Percent effect-size (mean difference between alive and dead patients / 
standard deviation) for the main predictors of mortality in univariate analysis. 
 
Figure 2. Relative (percent) reduction in prediction error rates of CLIF-C AD score as 
compared to Child-Pugh, MELD and MELD-Sodium scores. 
 
Figure 3. Predictive ability of CLIF-C AD score for 90-day mortality as compared to 
MELD, MELD-Sodium and Child-Pugh. 
 
Figure 4. Proposed algorithm for the use of EASL-CLIF Consortium predictive scores 
for ACLF and non-ACLF patients. The 3-month mortality of the low-risk group is 1.8% 
whereas the risk of mortality of the high-risk group is 31.3%. 
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Table 1. Baseline characteristics and outcome of patients without an Acute-on-Chronic 
Liver Failure (NO ACLF) in the CANONIC study and in the external validation datasets. 
Patients’ Characteristics Derivation set 
(CANONIC 
patients) 
(n=1016) 
External 
Validation set 
 (N=225) 
p-value 
Age (years) 57.6±12.4 54.9±10.7 0.001 
Male sex 638(62.8) 159(71.0%) 0.031 
 
Patients’ characteristics at study enrolment: 
Etiology of cirrhosis:    
Alcohol 468(49.0) 110(48.9) 0.461 
HCV 207(21.7) 41(18.2) 0.519 
Alcohol + HCV 92(9.6) 33(14.7) <0.001 
Presence of ascites 646(63.9) 148(65.8) 0.591 
Serum bilirubin (μmol/L) 79±95 68±59 0.096 
Serum creatinine (μmol/L) 85±32 81±29 0.085 
HE Grade I-II 255(25.1) 37(16.4) 0.007 
HE Grade III-IV 23(2.3) 18(8.0) 0.001 
Intern. Normalised Ratio 1.5±0.4 1.6±0.3 <0.001 
Serum sodium (mmol/L) 135±6 135±5.5 0.999 
White-cell count(x109 cells/L) 6.8±4.1 7.6±4.8 0.021 
Use of Vasopressors 159(15.7) 5(2.2) <0.001 
PaO2/FiO2 ≤200 
  Or 
SpO2/FiO2 ≤214 
7(0.8) 3(1.3) 
 
0.572 
 
Scores at study enrolment: 
MELD score 16±5 16±5 0.999 
MELD-Na Score 19±6 19±5 0.999 
Child-Pugh Score 9.3±2.0 9.1±1.9 0.171 
 
Mortality rates: 
   
28-Day mortality 47(4.6) 10(4.4) 0.954 
90-Day mortality 128(12.6) 22(9.8) 0.260 
6-Month mortality 186(18.3) 37(16.4) 0.565 
1-Year mortality 280(27.6) 47(21.0) 0.045 
 
Data are numbers of patients (%) or mean±SD.  
HE: Hepatic Encephalopathy. HRS: Hepato-renal syndrome. FIO2, fraction of inspired 
oxygen. PaO2, partial pressure of arterial oxygen. SpO2, pulse oximetric saturation. 
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Table 2. Predictive discrimination ability of CLIF-C AD score as compared to MELD and 
MELD-Sodium. Patients without ACLF at enrolment in CANONIC database. 
 CLIF-C AD 
Score 
C-index (95% 
CI) 
Child-Pugh 
Score  
C-index (95% 
CI) 
MELD Score 
C-index (95% 
CI) 
MELD-Na 
Score 
C-index (95% 
CI) 
CANONIC PATIENTS (N=1016) 
90-Day mortality 0.743(0.704-
0.783) 
0.651(0.601-
0.701) 
0.649(0.602-
0.697) 
0.681(0.633-
0.728) 
p-value vs CLIF-C 
ADs* 
 <0.001 <0.001 <0.001 
180-Day mortality 0.711(0.675-
0.747) 
0.635(0.593-
0.677) 
0.625(0.585-
0.665) 
0.655(0.615-
0.695) 
p-value vs CLIF-C 
ADs * 
 <0.001 <0.001 <0.001 
365-Day mortality 0.670(0.639-
0.702) 
0.613(0.578-
0.648) 
0.593(0.560-
0.627) 
0.618(0.584-
0.652) 
p-value vs CLIF-C 
ADs * 
 <0.001 <0.001 <0.001 
* p-values from the Integrated Discriminating Improvement (IDI) statistics test 
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Table 3. Predictive discrimination ability of CLIF-C AD score as compared to MELD and 
MELD-Sodium. Patients without ACLF at enrolment in the internal and external validation 
databases. 
 CLIF-C AD 
Score 
C-index (95% 
CI) 
Child-Pugh 
Score  
C-index (95% 
CI) 
MELD Score 
C-index (95% 
CI) 
MELD-Na 
Score 
C-index (95% 
CI) 
 
INTERNAL VALIDATION DATABASE. RANDOM SAMPLE OF CANONIC PATIENTS 
(N=500) 
90-Day mortality 0.726 (0.668-
0.784) 
0.608 (0.534-
0.682) 
0.631 (0.562-
0.700) 
0.652 (0.584-
0.720) 
p-value vs CLIF-C 
ADs* 
 <0.001 <0.001 0.002 
180-Day mortality 0.700 (0.646-
0.753) 
0.606 (0.544-
0.669) 
0.611 (0.552-
0.670) 
0.633 (0.573-
0.692) 
p-value vs CLIF-C 
ADs * 
 <0.001 <0.001 <0.001 
365-Day mortality 0.656 (0.608-
0.704) 
0.596 (0.544-
0.648) 
0.587 (0.537-
0.636) 
0.603 (0.553-
0.653) 
p-value vs CLIF-C 
ADs * 
 0.003 <0.001 0.002 
 
EXTERNAL VALIDATION DATABASE (N=225) 
90-Day mortality 0.744(0.629-
0.859) 
0.633(0.523-
0.742) 
0.647(0.545-
0.749) 
0.711(0.630-
0.793) 
p-value vs CLIF-C 
ADs * 
 0.043 0.013 0.299 
180-Day mortality 0.683(0.590-
0.775) 
0.627(0.541-
0.713) 
0.617(0.530-
0.704) 
0.654(0.576-
0.733) 
p-value vs CLIF-C 
ADs * 
 0.609 0.630 0.956 
365-Day mortality 0.662(0.579-
0.744) 
0.612(0.536-
0.689) 
0.592(0.513-
0.671) 
0.625 (0.551-
0.698) 
p-value vs CLIF-C 
ADs * 
 0.753 0.306 0.548 
* p-values from the Integrated Discriminating Improvement (IDI) statistics test 
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Table 4. Sequential use of the CLIF-C AD and MELD score to predict mortality in 
CANONIC patients without ACLF at enrolment and post-enrolment clinical and 
laboratory follow-up. 
 1-year mortality 
 CLIF-C AD score MELD score 
 C-index 
(95% CI) 
p-value 
vs 
baseline 
C-index 
(95% CI) 
p-value 
vs 
baseline 
Scores at enrolment 
(N=344) 
0·644 
(0·585-0·702) 
 0.591 
(0.535-
0.647) 
 
Scores after 48 hours 
(N=236) 
0·667 
(0·611- 0·734) 
0·443 0.579 
(0.515-
0.642) 
 
0.689 
Scores after 3-7 days 
(N=273) 
0·666 
(0·605- 0·728) 
0·463 0.612 
(0.549-
0.676) 
0.484 
Scores after 8-15 days 
(N=165) 
0.714 
(0.644-0.784) 
0.020 0.608 
(0.526-
0.689) 
0.571 
* p-value vs score estimates at enrolment 
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Figure 1 
 
Figure 2 
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 Figure 3 
 
 
AUROC p-value
(95% Confidence Interval)                    vs CLIF-C ADs
▬ CLIF-C ADs:              0.76 (0.71-0.80)
▬ MELDs: 0.66 (0.60-0.72) 0.0007
▬ MELD-Nas: 0.70 (0.65-0.76) 0.0245
▬ CPs: 0.65 (0.60-0.71) 0.0004
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Figure 4 
 
 
 
 
 
 
 
 
Admission of Cirrhotic patient with acute decompensation
Assess CLIF-C OF score for diagnosis of ACLF
ACLF present ACLF absent
CLIF-C ACLF score
High risk:
CLIF-C ADs≥60
3-month mortality<30%
CLIF-C AD score
Low risk:
CLIF-C ADs≤45
3-month mortality<2%
